Microbiome Biotech Enterome and Takeda sign Crohn's Deal Worth Up To $600 Million+
Enterome will receive an upfront payment of $50 million end is eligible to receive up to $640 in additional payments
Enterome and Takeda also have agreements targeting multiple other GI conditions
Enterome focuses on developing treatments derived from gut microbes rather than treatments that include live microbes
ENTEROME SA, on 10/23/18 announced it has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical Company Limited (“Takeda”). The agreement covers Enterome’s lead investigational drug candidate EB8018 in patients with Crohn’s disease, with the potential to expand to other gastrointestinal (GI) disorders and liver diseases.
Microbiotica Attracts Equity Investment from Seventure’s Health for Life Capital Fund
Seventure Partners, a specialist investor in the microbiome, commits new funding from Health for Life Capital™ and strengthens Microbiotica’s Board with microbiome sector expertise and know-how.
Seventure Joins founding investors, Cambridge Innovation Capital and IP Group, by committing £4m, bringing total equity raised to £12m.
To see the rest of this week's microbiome report and gain access to our microbiome database, subscirbe to our premium newsletter.